Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2020 | Nov. 16, 2020 | |
Cover [Abstract] | ||
Entity Registrant Name | Protagenic Therapeutics, Inc.\new | |
Entity Central Index Key | 0001022899 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2020 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business Flag | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 10,360,480 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2020 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Sep. 30, 2020 | Dec. 31, 2019 |
CURRENT ASSETS | ||
Cash | $ 988,574 | $ 798,623 |
Prepaid expenses | 13,405 | 43,354 |
TOTAL CURRENT ASSETS | 1,001,979 | 841,977 |
Equipment - net | 35 | 296 |
TOTAL ASSETS | 1,002,014 | 842,273 |
CURRENT LIABILITIES | ||
Accounts payable and accrued expenses | 521,835 | 865,047 |
Derivative liability | 190,315 | 332,222 |
TOTAL CURRENT LIABILITIES | 712,150 | 1,197,269 |
PIK convertible notes payable, net of debt discount | 1,027,689 | 174,821 |
PIK convertible notes payable, net of debt discount - related party | 282,895 | 104,549 |
TOTAL LIABILITIES | 2,022,734 | 1,476,639 |
STOCKHOLDERS' DEFICIT | ||
Preferred stock value | ||
Common stock, $.0001 par value, 100,000,000 shares authorized, 10,360,480 and 10,261,419 shares issued and outstanding at September 30 2020, and December 31, 2019 | 1,036 | 1,026 |
Additional paid-in-capital | 16,326,490 | 14,687,172 |
Accumulated deficit | (17,175,284) | (15,150,201) |
Accumulated other comprehensive loss | (172,963) | (172,364) |
TOTAL STOCKHOLDERS' DEFICIT | (1,020,720) | (634,366) |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | 1,002,014 | 842,273 |
Series B Convertible Preferred Stock [Member] | ||
STOCKHOLDERS' DEFICIT | ||
Preferred stock value | $ 1 | $ 1 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Sep. 30, 2020 | Dec. 31, 2019 |
Preferred stock, par value | $ 0.000001 | $ 0.000001 |
Preferred stock, shares authorized | 2,000,000 | 2,000,000 |
Preferred stock, shares issued | ||
Preferred stock, shares outstanding | ||
Common stock, par value | $ .0001 | $ .0001 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 10,360,480 | 10,261,419 |
Common stock, shares outstanding | 10,360,480 | 10,261,419 |
Series B Convertible Preferred Stock [Member] | ||
Preferred stock, par value | $ 0.000001 | $ 0.000001 |
Preferred stock, shares authorized | 18,000,000 | 18,000,000 |
Preferred stock, shares issued | 872,766 | 872,766 |
Preferred stock, shares outstanding | 872,766 | 872,766 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
OPERATING AND ADMINISTRATIVE EXPENSES | ||||
Research and development | $ 539,770 | $ 31,153 | $ 657,737 | $ 291,828 |
General and administrative | 552,246 | 158,469 | 1,356,990 | 1,057,073 |
TOTAL OPERATING AND ADMINISTRATIVE EXPENSES | 1,092,016 | 189,622 | 2,014,727 | 1,348,901 |
LOSS FROM OPERATIONS | (1,092,016) | (189,622) | (2,014,727) | (1,348,901) |
OTHER (EXPENSE) INCOME | ||||
Interest income | 17 | 1,108 | 494 | 2,314 |
Interest expense | (58,827) | (152,757) | ||
Realized gain on marketable securities | 4,435 | |||
Change in fair value of derivative liability | 104,718 | 65,207 | 141,907 | 341,107 |
TOTAL OTHER INCOME (EXPENSES) | 45,908 | 66,315 | (10,356) | 347,856 |
LOSS BEFORE TAX | (1,046,108) | (123,307) | (2,025,083) | (1,001,045) |
INCOME TAX EXPENSE | ||||
NET LOSS | (1,046,108) | (123,307) | (2,025,083) | (1,001,045) |
Other Comprehensive Loss - net of tax | ||||
Foreign exchange translation income (loss) | 736 | (20) | (599) | (7,398) |
TOTAL COMPREHENSIVE LOSS | $ (1,045,372) | $ (123,327) | $ (2,025,682) | $ (1,008,443) |
Net loss per common share - Basic and Diluted | $ (0.10) | $ (0.01) | $ (0.20) | $ (0.10) |
Weighted average common shares - Basic and Diluted | 10,275,758 | 10,261,419 | 10,274,005 | 10,261,419 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) | Series B Convertible Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Deficit [Member] | Accumulated Other Comprehensive Loss [Member] | Total |
Balance at Dec. 31, 2018 | $ 1 | $ 1,026 | $ 13,357,920 | $ (13,399,290) | $ (170,540) | $ (210,883) |
Balance, shares at Dec. 31, 2018 | 872,766 | 10,261,419 | ||||
Unrealized gain on marketable securities | 4,823 | 4,823 | ||||
Foreign currency translation gain/loss | (7,669) | (7,669) | ||||
Stock compensation - stock options | 451,141 | 451,141 | ||||
Net loss | (599,232) | (599,232) | ||||
Balance at Mar. 31, 2019 | $ 1 | $ 1,026 | 13,809,061 | (13,998,522) | (173,386) | (361,820) |
Balance, shares at Mar. 31, 2019 | 872,766 | 10,261,419 | ||||
Balance at Dec. 31, 2018 | $ 1 | $ 1,026 | 13,357,920 | (13,399,290) | (170,540) | (210,883) |
Balance, shares at Dec. 31, 2018 | 872,766 | 10,261,419 | ||||
Issuance of options for settlement of accrued payroll | ||||||
Debt discount from warrants issued to placement agents- offering cost | ||||||
Net loss | (1,001,045) | |||||
Balance at Sep. 30, 2019 | $ 1 | $ 1,026 | 14,208,687 | (14,400,335) | (173,115) | (363,736) |
Balance, shares at Sep. 30, 2019 | 872,766 | 10,261,419 | ||||
Balance at Mar. 31, 2019 | $ 1 | $ 1,026 | 13,809,061 | (13,998,522) | (173,386) | (361,820) |
Balance, shares at Mar. 31, 2019 | 872,766 | 10,261,419 | ||||
Foreign currency translation gain/loss | 291 | 291 | ||||
Stock compensation - stock options | 260,560 | 260,560 | ||||
Net loss | (278,506) | (278,506) | ||||
Balance at Jun. 30, 2019 | $ 1 | $ 1,026 | 14,069,621 | (14,277,028) | (173,095) | (379,475) |
Balance, shares at Jun. 30, 2019 | 872,766 | 10,261,419 | ||||
Foreign currency translation gain/loss | (20) | (20) | ||||
Stock compensation - stock options | 139,066 | 139,066 | ||||
Net loss | (123,307) | (123,307) | ||||
Balance at Sep. 30, 2019 | $ 1 | $ 1,026 | 14,208,687 | (14,400,335) | (173,115) | (363,736) |
Balance, shares at Sep. 30, 2019 | 872,766 | 10,261,419 | ||||
Balance at Dec. 31, 2019 | $ 1 | $ 1,026 | 14,687,172 | (15,150,201) | (172,364) | (634,366) |
Balance, shares at Dec. 31, 2019 | 872,766 | 10,261,419 | ||||
Foreign currency translation gain/loss | (2,419) | (2,419) | ||||
Stock compensation - stock options | 360,436 | 360,436 | ||||
Debt discount from beneficial conversion feature | 89,204 | 89,204 | ||||
Issuance of options for settlement of accrued payroll | 93,950 | 93,950 | ||||
Modification of warrants | 5,861 | 5,861 | ||||
Net loss | (498,589) | (498,589) | ||||
Balance at Mar. 31, 2020 | $ 1 | $ 1,026 | 15,236,623 | (15,648,790) | (174,783) | (585,923) |
Balance, shares at Mar. 31, 2020 | 872,766 | 10,261,419 | ||||
Balance at Dec. 31, 2019 | $ 1 | $ 1,026 | 14,687,172 | (15,150,201) | (172,364) | (634,366) |
Balance, shares at Dec. 31, 2019 | 872,766 | 10,261,419 | ||||
Issuance of options for settlement of accrued payroll | 93,950 | |||||
Debt discount from warrants issued to placement agents- offering cost | 192,162 | |||||
Net loss | (2,025,083) | |||||
Balance at Sep. 30, 2020 | $ 1 | $ 1,036 | 16,326,490 | 17,175,284 | (172,963) | (1,020,720) |
Balance, shares at Sep. 30, 2020 | 872,766 | 10,360,480 | ||||
Balance at Mar. 31, 2020 | $ 1 | $ 1,026 | 15,236,623 | (15,648,790) | (174,783) | (585,923) |
Balance, shares at Mar. 31, 2020 | 872,766 | 10,261,419 | ||||
Foreign currency translation gain/loss | 1,084 | 1,084 | ||||
Stock compensation - stock options | 304,148 | 304,148 | ||||
Debt discount from beneficial conversion feature | 15,000 | 15,000 | ||||
Debt discount from warrants issued to placement agents- offering cost | 86,968 | 86,968 | ||||
Net loss | (480,386) | (480,386) | ||||
Balance at Jun. 30, 2020 | $ 1 | $ 1,026 | 15,642,739 | (16,129,176) | (173,699) | (659,109) |
Balance, shares at Jun. 30, 2020 | 872,766 | 10,261,419 | ||||
Foreign currency translation gain/loss | 736 | 736 | ||||
Stock compensation - stock options | 458,567 | 458,567 | ||||
Stock issued for services | $ 10 | 119,990 | 120,000 | |||
Stock issued for services, shares | 99,061 | |||||
Debt discount from warrants issued to placement agents- offering cost | 105,194 | 105,194 | ||||
Net loss | (1,046,108) | (1,046,108) | ||||
Balance at Sep. 30, 2020 | $ 1 | $ 1,036 | $ 16,326,490 | $ 17,175,284 | $ (172,963) | $ (1,020,720) |
Balance, shares at Sep. 30, 2020 | 872,766 | 10,360,480 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net Loss | $ (2,025,083) | $ (1,001,045) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Depreciation expense | 249 | 254 |
Stock based compensation | 1,243,151 | 850,767 |
Change in fair value of the derivative liability | (141,907) | (341,107) |
Gain on sale of marketable securities | (4,435) | |
Amortization of debt discount | 104,169 | |
Modification of warrants | 5,861 | |
Changes in operating assets and liabilities | ||
Prepaid expenses | 29,949 | 73,867 |
Accounts payable and accrued expenses | (244,300) | 83,129 |
NET CASH USED IN OPERATING ACTIVITIES | (1,027,911) | (338,570) |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
Sale of marketable securities | 250,000 | |
NET CASH PROVIDED BY INVESTING ACTIVITIES | 250,000 | |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Debt discount from issuance costs paid on PIK convertible notes | (104,090) | |
Proceeds from PIK convertible notes | 1,177,500 | |
Proceeds from PIK convertible notes - related party | 150,000 | |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 1,223,410 | |
Effect of exchange rate on cash | (5,548) | 3,470 |
NET INCREASE (DECREASE) IN CASH | 189,951 | (85,100) |
CASH, BEGINNING OF PERIOD | 798,623 | 362,486 |
CASH, END OF PERIOD | 988,574 | 277,386 |
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION | ||
Cash paid for interest expense | ||
Cash paid for income taxes | ||
NONCASH FINANCING AND INVESTING TRANSACTIONS | ||
Unrealized (gain) loss on marketable securities | 4,823 | |
Debt discount from beneficial conversion feature | 104,204 | |
Debt discount from warrants issued to placement agents-offering cost | 192,162 | |
Issuance of options for settlement of accrued payroll | $ 93,950 |
Organization and Nature of Busi
Organization and Nature of Business | 9 Months Ended |
Sep. 30, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Nature of Business | NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Company Background Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), is a Delaware corporation with one subsidiary named Protagenic Therapeutics Canada (2006) Inc. (“PTI Canada”), a corporation formed in 2006 under the laws of the Province of Ontario, Canada. The Company was previously known as Atrinsic, Inc., a company that was once a reporting company under the Securities Exchange Act of 1934, but that, in 2012 and 2013, reorganized under Chapter 11 of the United States Bankruptcy Code and emerged from bankruptcy. On February 12, 2016, the Company acquired Protagenic Therapeutics, Inc. (“Prior Protagenic”) through a reverse merger. On February 12, 2016, Protagenic Acquisition Corp., a wholly-owned subsidiary of the Company, merged (the “Merger”) with and into Prior Protagenic. Prior Protagenic was the surviving corporation of the Merger. As a result of the Merger, the Company acquired the business of Prior Protagenic and has continued the existing business operations of Prior Protagenic as a wholly-owned subsidiary. On June 17, 2016, Prior Protagenic merged with and into the Company with the Company as the surviving corporation in the merger. Immediately thereafter, the Company changed its name from Atrinsic, Inc. to Protagenic Therapeutics, Inc. |
Going Concern
Going Concern | 9 Months Ended |
Sep. 30, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Going Concern | NOTE 2 - GOING CONCERN As shown in the accompanying consolidated financial statements, the Company has incurred significant reoccurring losses resulting in an accumulated deficit. The Company anticipates further losses in the development of its business. The Company had negative cash flows used in operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Based on its current forecast and budget, management believes that its cash resources will be sufficient to fund its operations at least until the end of the third quarter of 2021. Absent generation of sufficient revenue from the execution of the Company’s business plan and sales revenue is not anticipated before 2024, the Company will need to obtain debt or equity financing by the third quarter of 2021. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern. The accompanying financial statements have been prepared assuming the Company will continue as a going concern; no adjustments to the financial statements have been made to account for this uncertainty. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2020 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | NOTE 3 - SUMMARY OF SIGNFICANT ACCOUNTING POLICIES Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC” for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2020 and 2019. As this is an interim period financial statement, certain adjustments are not necessary as with a financial period of a full year. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2019, which contain the audited financial statements and notes thereto, for the years ended December 31, 2019 and 2018 included within the Company’s Form 10-K filed with the SEC on April 29, 2020. The interim results for the nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any future interim periods. Principles of consolidation The consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated in the consolidated financial statements. Reclassifications: Reclassifications of prior periods have been made to conform with current year presentation Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the consolidated financial statements include income tax provisions, valuation of stock options and warrants and assessment of deferred tax asset valuation allowance. Concentrations of Credit Risk The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. While the Company’s marketable securities are cash equivalents it is the Company’s policy to present them separately on the balance sheet. As of September 30, 2020 and December 31, 2019, the Company did not have any cash equivalents. Equipment Equipment is stated at cost less accumulated depreciation. Cost includes expenditures for computer equipment. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of equipment is depreciated using the straight-line method over the estimated useful lives of the related assets which is three years. Depreciation expense was nominal for the three and nine months ended September 30, 2020 and 2019. Marketable Securities The Company accounts for marketable debt securities, the only type of securities it owns, in accordance with sub-topic 320-10 of the FASB Accounting Standards Codification (“Sub-topic 320-10”). Pursuant to Paragraph 320-10-35-1, investments in debt securities that are classified as available for sale shall be measured subsequently at fair value in the consolidated balance sheets at each balance sheet date. Unrealized holding gains and losses for available-for-sale securities (including those classified as current assets) shall be excluded from earnings and reported in other comprehensive income until realized. During the nine months ended September 30, 2020 and 2019, the Company purchased $0 and sold $250,000 in marketable securities, respectively. As of September 30, 2020 and December 31, 2019, the Company owned marketable securities with a total value of $0 and $0, respectively. The Company recorded a realized gain on marketable securities of $0 and $4,435 for the nine months ended September 30, 2020 and 2019, respectively. As of September 30, 2020 and December 31, 2019, the Company held no marketable securities. Fair Value Measurements ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels are described below: Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company; Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants. The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short maturity of those instruments. Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated. The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of September 30, 2020. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrants liabilities $ 190,315 $ — $ — $ 190,315 $ 190,315 The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2019. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrants liabilities $ 332,222 $ — $ — $ 332,222 $ 332,222 The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2020 and the year ended December 31, 2019: Fair Value Measurement Using Level 3 Inputs Total Balance, December 31, 2018 676,079 Change in fair value of derivative warrants liabilities (343,857 ) Balance, December 31, 2019 $ 332,222 Change in fair value of derivative warrants liabilities (141,907 ) Balance, September 30, 2020 $ 190,315 The fair value of the derivative feature of the 127,346 and 295,945 warrants issued to the placement agent of the Company’s 2016 private offering (the “2016 Offering”) and to a holder of its debt for debt cancellation in connection with the Merger, respectively on the issuance dates and at the balance sheet date were calculated using a Black-Scholes option model valued with the following assumptions: December 31, 2019 September 30, 2020 Exercise price 1.25 1.25 Risk free interest rate 1.59 % 0.10 % Dividend yield 0.00 % 0.00 % Expected volatility 133 % 169 % Contractual term 1.15 Years 0.39 Years Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of measurement. Dividend yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future. Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term. Expected term: The Company’s expected term is based on the remaining contractual maturity of the warrants. During the nine months ended September 30, 2020 and 2019, the Company marked the derivative feature of the warrants to fair value and recorded a gain of $141,907 and a gain of $341,107 relating to the change in fair value, respectively. Derivative Liability The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10-05-4 and 815-40-25. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the consolidated statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then the related fair value is reclassified to equity. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date. Stock-Based Compensation The Company accounts for stock based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or canceled during the periods reported. If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur. Basic and Diluted Net (Loss) per Common Share Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the income statement. Potentially Outstanding For the nine Months For the Year Ended Conversion Feature Shares Common shares issuable under the conversion feature of preferred shares 872,766 872,766 Stock Options 4,391,472 3,835,366 Warrants 4,007,058 3,826,658 Convertible Notes 1,598,000 536,000 Total potentially outstanding dilutive common shares 10,869,296 9,070,790 Research and Development Research and development expenses are charged to operations as incurred. Foreign Currency Translation The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section 830-10-45”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash. The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the consolidated statements of income and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the consolidated statements of income and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the statement of income and comprehensive income (loss). Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary. Leases In February 2016, FASB issued Accounting Standards Update (“ASU”) 2016-02: Leases (Topic 842). The new guidance generally requires an entity to recognize on its balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018 and early adoption is permitted. The new standard requires a modified retrospective transition for existing leases to each prior reporting period presented or entered into after, the beginning of the earliest comparative period presented in the financial statements. This standard was adopted by the Company on January 1, 2018. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to carry forward the historical lease classification. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures. Recent Accounting Pronouncements Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements. |
Accounts Payable and Accrued Ex
Accounts Payable and Accrued Expenses | 9 Months Ended |
Sep. 30, 2020 | |
Payables and Accruals [Abstract] | |
Accounts Payable and Accrued Expenses | NOTE 4 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consist of the following at: September 30, 2020 December 31, 2019 Accounting $ 24,161 $ 36,161 Research and development 378,428 650,584 Legal 9,585 15,273 Other 109,661 163,029 Total $ 521,835 $ 865,047 On October 1, 2019, the Company entered into an agreement with a consultant for toxicology studies. The consultant quoted a commitment of approximately $988,000 as an estimate for the study. 50% of the total price was paid upon the signing of the agreement, 35% of the total price is to be paid upon completion of the in-life study, and the remaining 15% of the total price is to be paid upon the issuance of the report. If the Company cancels the study the Company will be required to pay a cancelation fee. If the cancelation happens prior to the arrival of the test animals then the Company will need to pay between 20% and 50% of the animal fees depending on when the cancellation happens. If the cancellation occurs after the animals arrive but before the study begins then the Company will be responsible for paying 50% of the protocol price plus a fee of $7,000 per room/week for animal husbandry until the animals can be relocated or disposed of. If the Company cancels the study after it has begun then the Company will need to pay any fees for procured items for the study and any nonrecoverable expenses incurred by the consultant. As of September 30, 2020 and December 31, 2019, the Company has paid $174,106 and $0 and there is a balance of $319,799 and $493,905 due, respectively. On February 13, 2020, the Company issued 187,497 options to the Company’s CFO to settle $93,950 in accrued compensations. The options are fully vested on issuance, have an exercise price of $1.75, and expire in 10 years from issuance. |
Derivative Liabilities
Derivative Liabilities | 9 Months Ended |
Sep. 30, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Liabilities | NOTE 5 - DERIVATIVE LIABILITIES Upon closing of the private placement transactions in 2016, the Company issued 127,346 and 295,945 warrants, respectively, to the placement agent of the 2016 Offering and to Strategic Bio Partners, a holder of the Company’s debt, for debt cancellation, respectively, to purchase the Company’s Series B Preferred Stock with an exercise price of $1.25 and a five-year term. Upon the effectiveness of our reverse stock split in July 2016, these became warrants to purchase our common stock on the same terms and conditions. The warrants, if exercised under the cashless provision, do not have an explicit limit on the number of shares that will be issued. |
Convertible Note Payable (PIK N
Convertible Note Payable (PIK Notes) | 9 Months Ended |
Sep. 30, 2020 | |
Debt Disclosure [Abstract] | |
Convertible Note Payable (PIK Notes) | NOTE 6 – CONVERTIBLE NOTE PAYABLE (PIK NOTES) Convertible Notes Payable During the fourth quarter of 2019, the Company entered into a series of unsecured convertible notes (the “Convertible Notes”). The Convertible Notes have a total principal amount of $420,000. The Convertible Notes accrue 6% interest per year payable on October 31, 2020 and on the end of each calendar year thereafter, payable by a corresponding increase in the principal amount of each Convertible Note that increases to 12% per year (the Default Rate”) in the case a default. The Company will pay (a “PIK Payment”) the interest due by adding such interest (including interest at the Default Rate) to the then-outstanding principal amount of the Convertible Notes on each interest payment date and on the maturity date. Each PIK Payment will be preceded by written notice from the Company to the Convertible Note holder setting forth in reasonable detail the amount of such PIK Payment and the principal amount of the Convertible Note following such PIK Payment. The Convertible Notes are due on November 6, 2023. The Convertible Notes are convertible into shares of the Company’s common stock with a conversion price of $1.25 per share, subject to adjustment in certain circumstances. During the second quarter of 2020, the Company issued additional unsecured Convertible Notes in the aggregate principal amount of $850,000. The notes accrue 6% interest per year payable on October 31, 2020 and on the end of each calendar year thereafter, payable by a corresponding increase in the principal amount of each note that increases to 12% per year in the case of the notes entering default. The Company will pay (a “PIK Payment”) the interest due by adding such interest (including interest at the Default Rate) to the then-outstanding principal amount of the Notes on each interest payment date and on the Maturity Date. Each PIK Payment will be preceded by written notice from the Company to the Note holder setting forth in reasonable detail the amount of such PIK Payment and the principal amount of the Note following such PIK Payment. The notes are due on November 6, 2023. The notes are convertible into shares of the Company’s common stock with an exercise price of $1.25 per share. During the third quarter of 2020, the Company issued additional unsecured Convertible Notes in the aggregate principal amount of $327,500. The notes accrue 6% interest per year payable on October 31, 2020 and on the end of each calendar year thereafter, payable by a corresponding increase in the principal amount of each note that increases to 12% per year in the case of the notes entering default. The Company will pay (a “PIK Payment”) the interest due by adding such interest (including interest at the Default Rate) to the then-outstanding principal amount of the Notes on each interest payment date and on the Maturity Date. Each PIK Payment will be preceded by written notice from the Company to the Note holder setting forth in reasonable detail the amount of such PIK Payment and the principal amount of the Note following such PIK Payment. The notes are due on November 6, 2023. The notes are convertible into shares of the Company’s common stock with an exercise price of $1.25 per share. The Company has evaluated the terms of the Convertible Notes and determined that there are no derivative features in the Convertible Notes. These Convertible Notes do have a beneficial conversion feature and recorded a total debt discount of $356,204 with $104,204 being recorded in the nine months ended September 30, 2020. During the nine months ended September 30, 2020 and 2019, the Company amortized $63,342 and $0 of the debt discount, respectively. At September 30, 2020 and December 31, 2019, the Company had an unamortized debt discount of $286,042 and $245,179, respectively. Katalyst Securities LLC acted as the Company’s placement agent (the “Placement Agent”) for the sale of the Convertible Notes. The Company paid the Placement Agent, including its sub-agents, a commission of 10% of the funds raised from the investors introduced by the Placement Agent. In addition, the Placement Agent will receive warrants to purchase a number of shares of Common Stock equal to 10% of the shares of Common Stock issuable upon conversion of the Notes sold to the investors who were introduced to us by the Placement Agent (See note 7). The Company recognized $104,090 in expenses related to the Placement Agent commission for this offering which were recorded as a debt discount. This debt discount is being amortized over the life of the notes from the private placement. Amortization for the nine months September 30, 2020 is nominal. As of September 30, 2020 and December 31, 2019, the Company owes $1,597,500 and $420,000 on the outstanding Convertible Notes, respectively. Maturity Date of Notes for Twelve Months Ending September 30, Amount due 2021 $ - 2022 - 2023 - 2024 1,597,500 2025 - Total $ 1,597,500 Convertible Notes Payable – Related Party During the fourth quarter of 2019, the Company issued unsecured Convertible Notes in the aggregate principal amount of $250,000 to related parties. The notes accrue 6% interest per year payable on October 31, 2020 and on the end of each calendar year thereafter, payable by a corresponding increase in the principal amount of each Convertible Note that increases to 12% per year in the case of the notes entering default. The Company will pay (a “PIK Payment”) the interest due by adding such interest (including interest at the Default Rate) to the then-outstanding principal amount of the Notes on each interest payment date and on the Maturity Date. Each PIK Payment will be preceded by written notice from the Company to the Note holder setting forth in reasonable detail the amount of such PIK Payment and the principal amount of the Note following such PIK Payment. The notes are due on November 6, 2023. The notes are convertible into shares of the Company’s common stock with an exercise price of $1.25 per share. During the second quarter of, 2020, the Company issued additional unsecured Convertible Notes in the aggregate principal amount of $50,000. The notes accrue 6% interest per year payable on October 31, 2020 and on the end of each calendar year thereafter, payable by a corresponding increase in the principal amount of each note that increases to 12% per year in the case of the notes entering default. The Company will pay (a “PIK Payment”) the interest due by adding such interest (including interest at the Default Rate) to the then-outstanding principal amount of the Notes on each interest payment date and on the Maturity Date. Each PIK Payment will be preceded by written notice from the Company to the Note holder setting forth in reasonable detail the amount of such PIK Payment and the principal amount of the Note following such PIK Payment. The notes are due on November 6, 2023. The notes are convertible into shares of the Company’s common stock with an exercise price of $1.25 per share. During the third quarter of, 2020, the Company issued additional unsecured Convertible Notes in the aggregate principal amount of $100,000. The notes accrue 6% interest per year payable on October 31, 2020 and on the end of each calendar year thereafter, payable by a corresponding increase in the principal amount of each note that increases to 12% per year in the case of the notes entering default. The Company will pay (a “PIK Payment”) the interest due by adding such interest (including interest at the Default Rate) to the then-outstanding principal amount of the Notes on each interest payment date and on the Maturity Date. Each PIK Payment will be preceded by written notice from the Company to the Note holder setting forth in reasonable detail the amount of such PIK Payment and the principal amount of the Note following such PIK Payment. The notes are due on November 6, 2023. The notes are convertible into shares of the Company’s common stock with an exercise price of $1.25 per share. The Company has evaluated the terms of the notes and determined that there are no derivative features in the note. The Convertible Notes issued to related parties have a beneficial conversion feature and, accordingly, the Company recorded a debt discount of $150,000 during the year ended December 31, 2019. No debt discount was recorded during the nine months ended September 30, 2020. During the nine months ended September 30, 2020 and 2019, the Company amortized $28,344 and $0 of the debt discount, respectively, on Convertible Notes issued to related parties. Additionally, a fee of $9,000 was expensed related to the notes. At September, 30, 2020 and December 31, 2019, the Company had an unamortized debt discount of $117,105 and $154,451, respectively, on Convertible Notes issued to related parties. As of September 30, 2020 and December 31, 2019, the Company owes $400,000 and $250,000 on the outstanding notes, respectively, held by related parties. Maturity Date of Notes for Twelve Months Ending September 30, Amount due 2021 $ - 2022 - 2023 - 2024 400,000 2025 - Total $ 400,000 |
Stockholders' Deficit
Stockholders' Deficit | 9 Months Ended |
Sep. 30, 2020 | |
Equity [Abstract] | |
Stockholders' Deficit | NOTE 7 - STOCKHOLDERS’ DEFICIT Stock-Based Compensation In connection with the consummation of the Merger completed on February 12, 2016, we adopted Prior Protagenic’s 2006 Employee, Director and Consultant Stock Plan (the “2006 Plan”). On June 17, 2016, our stockholders adopted the 2016 Plan and, as a result, we terminated the 2006 Plan. We will not grant any further awards under the 2006 Plan. All outstanding grants under the 2006 Plan will continue in effect in accordance with the terms of the particular grant and the 2006 Plan. Pursuant to the 2016 Plan, the Company’s Compensation Committee may grant awards to any employee, officer, director, consultant, advisor or other individual service provider of the Company or any subsidiary. On each of January 1, 2017, January 1, 2019 and January 1, 2020, pursuant to an annual “evergreen” provision contained in the 2016 Plan, the number of shares reserved for future grants was increased by 564,378 shares, or a total of 1,693,134 shares. As a result of these increases, as of December 31, 2019 and September 30, 2020, the aggregate number of shares of common stock available for awards under the 2016 Plan was 4,304,245 shares and 4,868,623 shares, respectively. Options issued under the 2016 Plan are exercisable for up to ten years from the date of issuance. There were 5,597,861 options outstanding as of September 30, 2020. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows: Exercise price $ 1.75 Expected dividend yield 0 % Risk free interest rate 0.64%-1.61 % Expected life in years 10 Expected volatility 140%-146 % There were 3,835,366 options outstanding as of December 31, 2019. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows: Exercise price $ 1.00 - $1.75 Expected dividend yield 0 % Risk free interest rate 2.09%-2.70 % Expected life in years 10 Expected volatility 137%-140 % The following is an analysis of the stock option grant activity under the Plan: Weighted Average Weighted Average Remaining Number Exercise Price Life Stock Options Outstanding December 31, 2018 3,846,299 $ 1.36 7.20 Granted 126,567 $ 1.15 9.20 Expired (137,500 ) $ 1.75 Outstanding December 31, 2019 3,835,366 $ 1.34 6.02 Granted 1,762,495 $ 1.75 9.47 Expired - $ - Outstanding September 30, 2020 5,597,861 $ 1.47 6.74 A summary of the status of the Company’s nonvested options as of September 30, 2020, and changes during the nine months ended September 30, 2020, is presented below: Nonvested Options Options Weighted- Average Exercise Price Nonvested at December 31, 2018 800,210 $ 1.63 Granted 126,567 $ 1.15 Vested (584,895 ) $ 1.46 Forfeited (137,500 ) $ 1.75 Nonvested at December, 2019 204,382 $ 1.74 Granted 1,762,495 $ 1.75 Vested (760,488 ) $ 1.39 Forfeited - $ - Nonvested at September 30, 2020 1,206,389 $ 1.75 As of September 30, 2020, the Company had 5,597,861 shares issuable under options outstanding at a weighted average exercise price of $1.47 and an intrinsic value of $1,407,792. As of December 31, 2019, the Company had 3,835,366 shares issuable under options outstanding at a weighted average exercise price of $1.34 and an intrinsic value of $635,536. The total number of options granted during the nine months ended September 30, 2020 and 2019 was 1,762,495 and 126,567, respectively. The exercise price for these options was $1.00 per share or $1.75 per share. The Company recognized compensation expense related to options issued of $458,567 and $139,066 during the three months ended September 30, 2020 and 2019, respectively, which is included in general and administrative expenses and research and development expenses. For the three months ended September 30, 2020, $351,696 of the stock compensation was related to employees and $106,871 was related to non-employees. The Company recognized compensation expense related to options issued of $1,123,151 and $850,767 during the nine months ended September 30, 2020 and 2019, respectively, which is included in general and administrative expenses and research and development expenses. For the nine months ended September 30, 2020, $858,884 of the stock compensation was related to employees and $264,267 was related to non-employees. As of September 30, 2020, the unamortized stock option expense was $701,991 with $563,267 being related to employees and $138,724 being related to non-employees. As of September 30, 2020, the weighted average period for the unamortized stock compensation to be recognized is 2.10 years. On February 25, 2019, the Company granted 101,567 options with an exercise price of $1.00 and a ten year term. 59,900 of these options vest immediately and 41,667 vest bi-weekly over two months. These options have a Black-Scholes value of $199,807. The Company issued 59,900 options for settlement of accounts payable totaling $29,850 and recorded a loss of $99,541 on the settlement of the accounts payable. On June 17, 2019, the Company granted 25,000 options with an exercise price of $1.75 and a ten year term. These options vest immediately and have a Black-Scholes value of $36,374. On February 21, 2020, the Company issued a total of 1,387,497 options to purchase shares of the Company’s common stock to sixteen individuals with 1,362,497 option going to twelve related parties. These options had a grant date fair value of $1,901,724. From these options, 187,497 options were used to settle $93,950 in accrued compensations. These options have an exercise price of $1.75. 187,497 of the options vest immediately, 510,000 of the options vest monthly over 12 months, 5,000 of the options vest monthly over 24 months, 420,000 of the options vest monthly over 36 months, and 265,000 of the options vest monthly over 48 months. These options were approved by the board of directors on February 13, 2020. On July 18, 2020, the Company issued 124,998 options to a related party. These options have an exercise price of $1.75 and a term of ten years. These options vest immediately and the grant date fair value of these options was $142,607. On July 18, 2020, the Company issued 105,000 options. These options have an exercise price of $1.75 and a term of ten years. These options vest monthly over four years and the grant date fair value of these options was $119,972. On July 18, 2020, the Board of Directors Increased the size of the Board from five directors to six directors and Appoint Jennifer Buell, Ph.D. as a member of the Board, effective immediately, to fill the vacancy created by such increase and to serve until the next annual meeting of shareholders. Dr. Buell was issued options to purchase 100,000 shares of the Company’s common stock at an exercise price of $1.75 per share. The options vest as follows: monthly over 48 months. In recognition of her upcoming service as a Director of the Company, Dr. Buell was issued 45,000 options that vest monthly over 12 months. In each case the vesting commenced on the date of grant, July 18, 2020. These options had a grant date fair value of $165,426. Warrants: In connection with the Merger, all of the issued and outstanding warrants to purchase shares of Prior Protagenic common stock converted, on a 1 for 1 basis, into new warrants (the “ New Warrants Simultaneously with the Merger and the 2016 Offering, New Warrants to purchase 3,403,367 shares of Series B Preferred Stock at an average exercise price of approximately $1.05 per share were issued to holders of Prior Protagenic warrants; additionally, the holder of $665,000 of our debt and $35,000 of accrued interest exchanged such debt for five-year warrants to purchase 295,945 shares of Series B Preferred Stock at $1.25 per share. Warrants to purchase 127,346 shares of Series B Preferred Stock at an exercise price of $1.25 per share were issued to the placement agent in connection with the 2016 Offering. These warrants to purchase 423,291 shares of Series B Preferred Stock have been recorded as derivative liabilities. All of these warrants automatically converted into warrants to purchase our common stock upon the effectiveness of our reverse stock split in July 2016. See Note 5. A summary of warrant issuances are as follows: Weighted Average Weighted Average Remaining Number Exercise Price Life Warrants Outstanding December 31, 2018 3,826,658 $ 1.05 3.69 Granted - - - Outstanding December 31, 2019 3,826,658 $ 1.05 2.69 Granted 180,400 1.25 5.00 Outstanding September 30, 2020 4,007,058 $ 1.06 2.12 As of September 30, 2020, the Company had 4,007,058 shares issuable under warrants outstanding at a weighted average exercise price of $1.06 and an intrinsic value of $643,130. As of December 31, 2019, the Company had 3,826,658 shares issuable under warrants outstanding at a weighted average exercise price of $1.05 and an intrinsic value of $1,375,990. On February 21, 2020, the Company extended the expiration date for 100,000 warrants to purchase shares of the Company’s common stock. The expiration date was extended by two years from January 2, 2020 to January 2, 2022. These warrants have exercise price of $1.25 and are fully vested. The company recognized $5,861 in stock compensation as part of this modification. On June 30, 2020, the Company issued 81,600 warrants to purchase shares of the Company’s common stock. These warrants vest immediately, had an exercise price of $1.25 and a term of 5 years. These warrants have a Black-Scholes value of $86,968, which is being amortized over the life of the notes from the private placement. These warrants were issued as compensation to the placement agents in connection with the Company’s private placement offering of debt and recorded as a debt discount. The Company recognized amortization of debt discount related to warrants issued of $6,643 and $0 during the nine months ended September 30, 2020 and 2019, respectively, which is included in general and administrative expenses. During the third quarter of 2020, the Company issued 98,800 warrants to purchase shares of the Company’s common stock. These warrants vest immediately, had an exercise price of $1.25 and a term of 5 years. These warrants have a Black-Scholes value of $105,194 which is being amortized over the life of the notes from the private placement. These warrants were issued as compensation to the placement agents in connection with the Company’s private placement offering of debt. The Company recognized amortization of debt discount related to warrants issued of $5,840 and $0 during the nine months ended September 30, 2020 and 2019, respectively, which is included in general and administrative expenses. |
Collaborative Agreements
Collaborative Agreements | 9 Months Ended |
Sep. 30, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Collaborative Agreements | NOTE 8 - COLLABORATIVE AGREEMENTS The Company and the University of Toronto, a stockholder of the Company (the “University”) entered into an agreement effective December 14, 2004 (the “Research Agreement”) for the performance of a research project titled “Evidence for existence of TCAP receptors in neurons” (the “Project”). The Research Agreement expired on March 31, 2013. The Company and the University entered into an agreement effective April 1, 2014 (the “New Research Agreement”) for the performance of a research project titled “Teneurin C-terminal Associated Peptide (“TCAP”) mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism” (the “New Project”). The New Project is to perform research related to work done by Dr. David A. Lovejoy, a professor at the University and stockholder of the Company, in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, Dr. Lovejoy entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 30, 2016. In February 2017, the New Research Agreement was extended to December 31, 2017. The extension allowed for further development of the technologies and use of their applications. On April 10, 2018, the agreement was amended and the research agreement has been further extended to December 31, 2023. Prior to January 1, 2016, the University has been granted 25,000 stock options which are fully vested at the exercise price of $1.00 exercisable over a ten year period which ends on April 1, 2022. As of September 30, 2020, Dr. David Lovejoy of the University has been granted 553,299 stock options, of which 517,987 are fully vested. These have an exercise price of $1.00, $1.25 or 1.75 and are exercisable over ten or thirteen year periods which end either on March 30, 2021, December 1, 2022, April 15, 2026, March 1, 2027, October 16, 2027 or on February 13, 2030. The sponsorship research and development expenses pertaining to the Research Agreements were $0 and $63,787 for the nine months ended September 30, 2020 and 2019, respectively. |
Licensing Agreements
Licensing Agreements | 9 Months Ended |
Sep. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Licensing Agreements | NOTE 9 - LICENSING AGREEMENTS On July 31, 2005, the Company had entered into a Technology License Agreement (“License Agreement”) with the University pursuant to which the University agreed to license to the Company patent rights and other intellectual property, among other things (the “Technologies”). The Technology License Agreement was amended on February 18, 2015 and currently does not provide for an expiration date. Pursuant to the License Agreement and its amendment, the Company obtained an exclusive worldwide license to make, have made, use, sell and import products based upon the Technologies, or to sublicense the Technologies in accordance with the terms of the License Agreement and amendment. In consideration, the Company agreed to pay to the University a royalty payment of 2.5% of net sales of any product based on the Technologies. If the Company elects to sublicense any rights under the License Agreement and amendment, the Company agrees to pay to the University 10% of any up-front sub-license fees for any sub-licenses that occurred on or after September 9, 2006, and, on behalf of the sub-licensee, 2.5% of net sales by the sub-licensee of all products based on the Technologies. The Company had no sales revenue for the nine months ended September 30, 2020 and 2019 and therefore was not subject to paying any royalties. In the event the Company fails to provide the University with semi-annual reports on the progress or fails to continue to make reasonable commercial efforts towards obtaining regulatory approval for products based on the Technologies, the University may convert our exclusive license into a non-exclusive arrangement. Interest on any amounts owed under the License Agreement and amendment will be at 3% per annum. All intellectual property rights resulting from the Technologies or improvements thereon will remain the property of the other inventors and/or Dr. Lovejoy, and/or the University, as the case may be. The Company has agreed to pay all out-of- pocket filing, prosecution and maintenance expenses in connection with any patents relating to the Technologies. In the case of infringement upon any patents relating to the Technologies, the Company may elect, at its own expense, to bring a cause of action asserting such infringement. In such a case, after deducting any legal expenses the Company may incur, any settlement proceeds will be subject to the 2.5% royalty payment owed to the University under the License Agreement and amendment. The patent applications were made in the name of Dr. Lovejoy and other inventors, but the Company’s exclusive, worldwide rights to such patent applications are included in the License Agreement and its amendment with the University. The Company maintains exclusive licensing agreements and it currently controls the five intellectual patent properties. Legal Proceedings From time to time we may be named in claims arising in the ordinary course of business. Currently, no legal proceedings, government actions, administrative actions, investigations or claims are pending against us or involve us that, in the opinion of our management, could reasonably be expected to have a material adverse effect on our business and financial condition. |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Sep. 30, 2020 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | NOTE 10 – RELATED PARTY TRANSACTIONS The Company is provided free office space consisting of a conference room by the Company Executive Chairman, Dr. Armen. The Company does not pay any rent for the use of this space. This space is used for quarterly board meetings and our annual shareholder meeting. On February 13, 2020, the Company issued 50,000 options to purchase common stock to a related party. These options had an exercise price of $1.75 and a term of 48 months. (See Note 7) On July 18, 2020, the Board of Directors increased the size of the Board from five directors to six directors and appointed Jennifer Buell, Ph.D. as a member of the Board, effective immediately, to fill the vacancy created by such increase and to serve until the next annual meeting of shareholders. Dr. Buell was issued options to purchase 100,000 shares of the Company’s common stock at an exercise price of $1.75 per share. The options vest as follows: monthly over 48 months. In recognition of her upcoming service as a Director of the Company, Dr. Buell was issued 45,000 options that vest monthly over 12 months. In each case the vesting commenced on the date of grant, July 18, 2020. These options had a grant date fair value of $165,426. (See Note 7) |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the rules and regulations of the Securities and Exchange Commission (“SEC” for interim financial information. In the opinion of the Company’s management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal, recurring adjustments, considered necessary for a fair presentation of the results for the interim periods ended September 30, 2020 and 2019. As this is an interim period financial statement, certain adjustments are not necessary as with a financial period of a full year. Although management believes that the disclosures in these unaudited condensed consolidated financial statements are adequate to make the information presented not misleading, certain information and footnote disclosures normally included in financial statements that have been prepared in accordance U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s financial statements for the year ended December 31, 2019, which contain the audited financial statements and notes thereto, for the years ended December 31, 2019 and 2018 included within the Company’s Form 10-K filed with the SEC on April 29, 2020. The interim results for the nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or for any future interim periods. |
Principles of Consolidation | Principles of consolidation The consolidated financial statements include the accounts of Protagenic Therapeutics, Inc., and its wholly owned Canadian subsidiary, PTI Canada. All significant intercompany balances and transactions have been eliminated in the consolidated financial statements. |
Reclassifications | Reclassifications: Reclassifications of prior periods have been made to conform with current year presentation |
Use of Estimates | Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates. Significant estimates underlying the consolidated financial statements include income tax provisions, valuation of stock options and warrants and assessment of deferred tax asset valuation allowance. |
Concentrations of Credit Risk | Concentrations of Credit Risk The Company maintains its cash accounts at financial institutions which are insured by the Federal Deposit Insurance Corporation. At times, the Company may have deposits in excess of federally insured limits. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. While the Company’s marketable securities are cash equivalents it is the Company’s policy to present them separately on the balance sheet. As of September 30, 2020 and December 31, 2019, the Company did not have any cash equivalents. |
Equipment | Equipment Equipment is stated at cost less accumulated depreciation. Cost includes expenditures for computer equipment. Maintenance and repairs are charged to expense as incurred. When assets are sold, retired, or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in operations. The cost of equipment is depreciated using the straight-line method over the estimated useful lives of the related assets which is three years. Depreciation expense was nominal for the three and nine months ended September 30, 2020 and 2019. |
Marketable Securities | Marketable Securities The Company accounts for marketable debt securities, the only type of securities it owns, in accordance with sub-topic 320-10 of the FASB Accounting Standards Codification (“Sub-topic 320-10”). Pursuant to Paragraph 320-10-35-1, investments in debt securities that are classified as available for sale shall be measured subsequently at fair value in the consolidated balance sheets at each balance sheet date. Unrealized holding gains and losses for available-for-sale securities (including those classified as current assets) shall be excluded from earnings and reported in other comprehensive income until realized. During the nine months ended September 30, 2020 and 2019, the Company purchased $0 and sold $250,000 in marketable securities, respectively. As of September 30, 2020 and December 31, 2019, the Company owned marketable securities with a total value of $0 and $0, respectively. The Company recorded a realized gain on marketable securities of $0 and $4,435 for the nine months ended September 30, 2020 and 2019, respectively. As of September 30, 2020 and December 31, 2019, the Company held no marketable securities. |
Fair Value Measurements | Fair Value Measurements ASC 820, “Fair Value Measurements and Disclosure,” defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, not adjusted for transaction costs. ASC 820 also establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels giving the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels are described below: Level 1 Inputs – Unadjusted quoted prices in active markets for identical assets or liabilities that is accessible by the Company; Level 2 Inputs – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; Level 3 Inputs – Unobservable inputs for the asset or liability including significant assumptions of the Company and other market participants. The carrying amount of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses approximate their fair value because of the short maturity of those instruments. Transactions involving related parties cannot be presumed to be carried out on an arm’s-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm’s-length transactions unless such representations can be substantiated. The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of September 30, 2020. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrants liabilities $ 190,315 $ — $ — $ 190,315 $ 190,315 The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2019. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrants liabilities $ 332,222 $ — $ — $ 332,222 $ 332,222 The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2020 and the year ended December 31, 2019: Fair Value Measurement Using Level 3 Inputs Total Balance, December 31, 2018 676,079 Change in fair value of derivative warrants liabilities (343,857 ) Balance, December 31, 2019 $ 332,222 Change in fair value of derivative warrants liabilities (141,907 ) Balance, September 30, 2020 $ 190,315 The fair value of the derivative feature of the 127,346 and 295,945 warrants issued to the placement agent of the Company’s 2016 private offering (the “2016 Offering”) and to a holder of its debt for debt cancellation in connection with the Merger, respectively on the issuance dates and at the balance sheet date were calculated using a Black-Scholes option model valued with the following assumptions: December 31, 2019 September 30, 2020 Exercise price 1.25 1.25 Risk free interest rate 1.59 % 0.10 % Dividend yield 0.00 % 0.00 % Expected volatility 133 % 169 % Contractual term 1.15 Years 0.39 Years Risk-free interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note with a similar expected term on the date of measurement. Dividend yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring dividends in the near future. Volatility: The Company calculates the expected volatility of the stock price based on the corresponding volatility of the Company’s peer group stock price for a period consistent with the warrants’ expected term. Expected term: The Company’s expected term is based on the remaining contractual maturity of the warrants. During the nine months ended September 30, 2020 and 2019, the Company marked the derivative feature of the warrants to fair value and recorded a gain of $141,907 and a gain of $341,107 relating to the change in fair value, respectively. |
Derivative Liability | Derivative Liability The Company evaluates its options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with ASC 815-10-05-4 and 815-40-25. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market each balance sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the consolidated statement of operations as other income or expense. Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then the related fair value is reclassified to equity. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within 12 months of the balance sheet date. |
Stock-Based Compensation | Stock-Based Compensation The Company accounts for stock based compensation costs under the provisions of ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense related to the fair value of stock based compensation awards that are ultimately expected to vest. Stock based compensation expense recognized includes the compensation cost for all stock based payments granted to employees, officers, non-employees, and directors based on the grant date fair value estimated in accordance with the provisions of ASC 718. ASC. 718 is also applied to awards modified, repurchased, or canceled during the periods reported. If any award granted under the Company’s 2016 Equity Compensation Plan (the “2016 Plan”) payable in shares of common stock is forfeited, cancelled, or returned for failure to satisfy vesting requirements, otherwise terminates without payment being made, or if shares of common stock are withheld to cover withholding taxes on options or other awards, the number of shares of common stock as to which such option or award was forfeited, or which were withheld, will be available for future grants under the 2016 Plan. The Company recognizes the impact of forfeitures when they occur. |
Basic and Diluted Net (Loss) Per Common Share | Basic and Diluted Net (Loss) per Common Share Basic (loss) per common share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding for each period. Diluted (loss) per share is computed by dividing the net (loss) by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable through the common stock equivalents. The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the income statement. Potentially Outstanding For the nine Months For the Year Ended Conversion Feature Shares Common shares issuable under the conversion feature of preferred shares 872,766 872,766 Stock Options 4,391,472 3,835,366 Warrants 4,007,058 3,826,658 Convertible Notes 1,598,000 536,000 Total potentially outstanding dilutive common shares 10,869,296 9,070,790 |
Research and Development | Research and Development Research and development expenses are charged to operations as incurred. |
Foreign Currency Translation | Foreign Currency Translation The Company follows Section 830-10-45 of the FASB Accounting Standards Codification (“Section 830-10-45”) for foreign currency translation to translate the financial statements of the foreign subsidiary from the functional currency, generally the local currency, into U.S. Dollars. Section 830-10-45 sets out the guidance relating to how a reporting entity determines the functional currency of a foreign entity (including of a foreign entity in a highly inflationary economy), re-measures the books of record (if necessary), and characterizes transaction gains and losses. Pursuant to Section 830-10-45, the assets, liabilities, and operations of a foreign entity shall be measured using the functional currency of that entity. An entity’s functional currency is the currency of the primary economic environment in which the entity operates; normally, that is the currency of the environment, or local currency, in which an entity primarily generates and expends cash. The functional currency of each foreign subsidiary is determined based on management’s judgment and involves consideration of all relevant economic facts and circumstances affecting the subsidiary. Generally, the currency in which the subsidiary transacts a majority of its transactions, including billings, financing, payroll and other expenditures, would be considered the functional currency, but any dependency upon the parent and the nature of the subsidiary’s operations must also be considered. If a subsidiary’s functional currency is deemed to be the local currency, then any gain or loss associated with the translation of that subsidiary’s financial statements is included in accumulated other comprehensive income. However, if the functional currency is deemed to be the U.S. Dollar, then any gain or loss associated with the re-measurement of these financial statements from the local currency to the functional currency would be included in the consolidated statements of income and comprehensive income (loss). If the Company disposes of foreign subsidiaries, then any cumulative translation gains or losses would be recorded into the consolidated statements of income and comprehensive income (loss). If the Company determines that there has been a change in the functional currency of a subsidiary to the U.S. Dollar, any translation gains or losses arising after the date of change would be included within the statement of income and comprehensive income (loss). Based on an assessment of the factors discussed above, the management of the Company determined its subsidiary’s local currency (i.e. the Canadian dollar) to be the functional currency for its foreign subsidiary. |
Leases | Leases In February 2016, FASB issued Accounting Standards Update (“ASU”) 2016-02: Leases (Topic 842). The new guidance generally requires an entity to recognize on its balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The standard will be effective for the first interim period within annual reporting periods beginning after December 15, 2018 and early adoption is permitted. The new standard requires a modified retrospective transition for existing leases to each prior reporting period presented or entered into after, the beginning of the earliest comparative period presented in the financial statements. This standard was adopted by the Company on January 1, 2018. The Company elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to carry forward the historical lease classification. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements Management does not believe that any recently issued, but not effective, accounting standards, if currently adopted, would have a material effect on the Company’s financial statements. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Accounting Policies [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of September 30, 2020. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrants liabilities $ 190,315 $ — $ — $ 190,315 $ 190,315 The following table provides a summary of financial instruments that are measured at fair value on a recurring basis as of December 31, 2019. Carrying Fair Value Measurement Using Value Level 1 Level 2 Level 3 Total Derivative warrants liabilities $ 332,222 $ — $ — $ 332,222 $ 332,222 |
Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation | The table below provides a summary of the changes in fair value, including net transfers in and/or out, of all financial assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the nine months ended September 30, 2020 and the year ended December 31, 2019: Fair Value Measurement Using Level 3 Inputs Total Balance, December 31, 2018 676,079 Change in fair value of derivative warrants liabilities (343,857 ) Balance, December 31, 2019 $ 332,222 Change in fair value of derivative warrants liabilities (141,907 ) Balance, September 30, 2020 $ 190,315 |
Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques | December 31, 2019 September 30, 2020 Exercise price 1.25 1.25 Risk free interest rate 1.59 % 0.10 % Dividend yield 0.00 % 0.00 % Expected volatility 133 % 169 % Contractual term 1.15 Years 0.39 Years |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share | The effect of dilution on net loss becomes anti-dilutive and therefore is not reflected on the income statement. Potentially Outstanding For the nine Months For the Year Ended Conversion Feature Shares Common shares issuable under the conversion feature of preferred shares 872,766 872,766 Stock Options 4,391,472 3,835,366 Warrants 4,007,058 3,826,658 Convertible Notes 1,598,000 536,000 Total potentially outstanding dilutive common shares 10,869,296 9,070,790 |
Accounts Payable and Accrued _2
Accounts Payable and Accrued Expenses (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Payables and Accruals [Abstract] | |
Schedule of Accounts Payable and Accrued Expenses | Accounts payable and accrued expenses consist of the following at: September 30, 2020 December 31, 2019 Accounting $ 24,161 $ 36,161 Research and development 378,428 650,584 Legal 9,585 15,273 Other 109,661 163,029 Total $ 521,835 $ 865,047 |
Convertible Note Payable (PIK_2
Convertible Note Payable (PIK Notes) (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Convertible Notes Payable [Member] | |
Schedule of Maturity Date of Notes | Maturity Date of Notes for Twelve Months Ending September 30, Amount due 2021 $ - 2022 - 2023 - 2024 1,597,500 2025 - Total $ 1,597,500 |
Convertible Notes Payable - Related Party [Member] | |
Schedule of Maturity Date of Notes | Maturity Date of Notes for Twelve Months Ending September 30, Amount due 2021 $ - 2022 - 2023 - 2024 400,000 2025 - Total $ 400,000 |
Stockholders' Deficit (Tables)
Stockholders' Deficit (Tables) | 9 Months Ended |
Sep. 30, 2020 | |
Equity [Abstract] | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions | There were 5,597,861 options outstanding as of September 30, 2020. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows: Exercise price $ 1.75 Expected dividend yield 0 % Risk free interest rate 0.64%-1.61 % Expected life in years 10 Expected volatility 140%-146 % There were 3,835,366 options outstanding as of December 31, 2019. The fair value of each stock option granted was estimated using the Black-Scholes assumptions and or factors as follows: Exercise price $ 1.00 - $1.75 Expected dividend yield 0 % Risk free interest rate 2.09%-2.70 % Expected life in years 10 Expected volatility 137%-140 % |
Schedule of Share-based Compensation, Stock Options, Activity | The following is an analysis of the stock option grant activity under the Plan: Weighted Average Weighted Average Remaining Number Exercise Price Life Stock Options Outstanding December 31, 2018 3,846,299 $ 1.36 7.20 Granted 126,567 $ 1.15 9.20 Expired (137,500 ) $ 1.75 Outstanding December 31, 2019 3,835,366 $ 1.34 6.02 Granted 1,762,495 $ 1.75 9.47 Expired - $ - Outstanding September 30, 2020 5,597,861 $ 1.47 6.74 |
Schedule of Share-based Compensation Nonvested Shares | A summary of the status of the Company’s nonvested options as of September 30, 2020, and changes during the nine months ended September 30, 2020, is presented below: Nonvested Options Options Weighted- Average Exercise Price Nonvested at December 31, 2018 800,210 $ 1.63 Granted 126,567 $ 1.15 Vested (584,895 ) $ 1.46 Forfeited (137,500 ) $ 1.75 Nonvested at December, 2019 204,382 $ 1.74 Granted 1,762,495 $ 1.75 Vested (760,488 ) $ 1.39 Forfeited - $ - Nonvested at September 30, 2020 1,206,389 $ 1.75 |
Summary of Warrant Issuances | A summary of warrant issuances are as follows: Weighted Average Weighted Average Remaining Number Exercise Price Life Warrants Outstanding December 31, 2018 3,826,658 $ 1.05 3.69 Granted - - - Outstanding December 31, 2019 3,826,658 $ 1.05 2.69 Granted 180,400 1.25 5.00 Outstanding September 30, 2020 4,007,058 $ 1.06 2.12 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | |
Cash equivalents | |||||
Proceeds from sale of marketable securities | $ 250,000 | ||||
Marketable securities | 0 | 0 | $ 0 | ||
Marketable securities, gross realized gain (loss) | 4,435 | ||||
Payments to acquire marketable securities | |||||
Derivative, gain (loss) on derivative, net | $ 104,718 | $ 65,207 | $ 141,907 | $ 341,107 | |
Dividend Yield [Member] | |||||
Fair value measurements, input percentage | 0.00% | ||||
Private Placement [Member] | |||||
Fair value of derivative feature | 127,346 | ||||
Class of warrant or right, issued | 295,945 | ||||
Equipment [Member] | |||||
Property, plant and equipment, useful life | 3 years |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) | Sep. 30, 2020 | Dec. 31, 2019 |
Reported Value Measurement [Member] | ||
Derivative warrants liabilities | $ (190,315) | $ (332,222) |
Estimate of Fair Value Measurement [Member] | ||
Derivative warrants liabilities | (190,315) | (332,222) |
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member] | ||
Derivative warrants liabilities | ||
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member] | ||
Derivative warrants liabilities | ||
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member] | ||
Derivative warrants liabilities | $ (190,315) | $ (332,222) |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - USD ($) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2020 | Dec. 31, 2019 | |
Accounting Policies [Abstract] | ||
Balance at beginning | $ 332,222 | $ 676,079 |
Change in fair value of derivative warrants liabilities | (141,907) | (343,857) |
Balance at end | $ 190,315 | $ 332,222 |
Summary of Significant Accoun_7
Summary of Significant Accounting Policies - Schedule of Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques (Details) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2020$ / shares | Dec. 31, 2019$ / shares | |
Measurement Input, Exercise Price [Member] | ||
Share price | $ 1.25 | $ 1.25 |
Measurement Input, Risk Free Interest Rate [Member] | ||
Derivative liability measurement input | 0.0010 | 0.0159 |
Dividend Yield [Member] | ||
Derivative liability measurement input | 0 | 0 |
Expected Volatility [Member] | ||
Derivative liability measurement input | 1.69 | 1.33 |
Contractual Term [Member] | ||
Derivative liability measurement input, contractual term | 4 months 20 days | 1 year 1 month 24 days |
Summary of Significant Accoun_8
Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2020 | Dec. 31, 2019 | |
Total potentially outstanding dilutive common shares | 10,869,296 | 9,070,790 |
Conversion Feature Shares [Member] | ||
Total potentially outstanding dilutive common shares | 872,766 | 872,766 |
Stock Options [Member] | ||
Total potentially outstanding dilutive common shares | 4,391,472 | 3,835,366 |
Warrant [Member] | ||
Total potentially outstanding dilutive common shares | 4,007,058 | 3,826,658 |
Convertible Notes [Member] | ||
Total potentially outstanding dilutive common shares | 1,598,000 | 536,000 |
Accounts Payable and Accrued _3
Accounts Payable and Accrued Expenses (Details Narrative) - USD ($) | Feb. 13, 2020 | Sep. 30, 2020 | Dec. 31, 2019 | Oct. 02, 2019 | Dec. 31, 2018 |
Stock option, exercise price | $ 1.47 | $ 1.34 | $ 1.36 | ||
Option term | 6 years 7 days | 7 years 2 months 12 days | |||
Toxicology Studies [Member] | |||||
Estimate for study description | On October 1, 2019, the Company entered into an agreement with a consultant for toxicology studies. The consultant quoted a commitment of approximately $988,000 as an estimate for the study. 50% of the total price was paid upon the signing of the agreement, 35% of the total price is to be upon completion of the in-life study, and the remaining 15% of the total price is to be paid upon the issuance of the report. If the Company cancels the study the Company will be required to pay a cancelation fee. If the cancelation happens prior to the arrival of the test animals then the Company will need to pay between 20% and 50% of the animal fees depending on when the cancellation happens. If the cancellation occurs after the animals arrive but before the study begins then the Company will be responsible for paying 50% of the protocol price plus a fee of $7,000 per room/week for animal husbandry until the animals can be relocated or disposed of. If the Company cancels the study after it has begun then the Company will need to pay any fees for procured items for the study and any nonrecoverable expenses incurred by the consultant. | ||||
Commitment cost paid | $ 174,106 | $ 0 | |||
Balance due amount | $ 319,799 | $ 493,905 | |||
Consultant [Member] | |||||
Estimate commitment amount | $ 988,000 | ||||
CFO [Member] | |||||
Issuance of stock option share based compensation | 187,497 | ||||
Accrued compensation | $ 93,950 | ||||
Stock option, exercise price | $ 1.75 | ||||
Option term | 10 years |
Accounts Payable and Accrued _4
Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($) | Sep. 30, 2020 | Dec. 31, 2019 |
Payables and Accruals [Abstract] | ||
Accounting | $ 24,161 | $ 36,161 |
Research and development | 378,428 | 650,584 |
Legal | 9,585 | 15,273 |
Other | 109,661 | 163,029 |
Total | $ 521,835 | $ 865,047 |
Derivative Liabilities (Details
Derivative Liabilities (Details Narrative) - Private Placement [Member] - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2020 | Dec. 31, 2016 | |
Class of warrant or right, issued during period | 295,945 | |
Series B Preferred Stock [Member] | ||
Class of warrant or right, issued during period | 127,346 | |
Class of warrant or right, exercise price of warrants or rights | $ 1.25 | |
Class of warrant or right, expiration period | 5 years | |
Series B Preferred Stock [Member] | Debt Settlement [Member] | Strategic Bio Partners [Member] | ||
Class of warrant or right, issued during period | 295,945 | |
Class of warrant or right, exercise price of warrants or rights | $ 1.25 | |
Class of warrant or right, expiration period | 5 years |
Convertible Note Payable (PIK_3
Convertible Note Payable (PIK Notes) (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2020 | Jun. 30, 2020 | Dec. 31, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | |
Debt beneficial conversion feature | $ 104,204 | ||||
Debt amortized debt discount | $ 104,169 | ||||
Placement Agent - Katalyst Securities LLC [Member] | |||||
Commission percentage terms | The Company paid the Placement Agent, including its sub-agents, a commission of 10% of the funds raised from the investors introduced by the Placement Agent. In addition, the Placement Agent will receive warrants to purchase a number of shares of Common Stock equal to 10% of the shares of Common Stock issuable upon conversion of the Notes sold to the investors who were introduced to us by the Placement Agent (See note 7). The Company recognized $104,090 in expenses related to the Placement Agent commission for this offering which were recorded as a debt discount. | ||||
Commission | $ 104,090 | ||||
Unsecured Convertible Notes [Member] | |||||
Convertible note principle amount | $ 327,500 | $ 850,000 | $ 420,000 | $ 327,500 | |
Debt interest percentage | 6.00% | 6.00% | 6.00% | 6.00% | |
Increase in interest rate | 12.00% | 12.00% | 12.00% | ||
Maturity date | Nov. 6, 2023 | Nov. 6, 2023 | Nov. 6, 2023 | ||
Conversion exercise price | $ 1.25 | $ 1.25 | $ 1.25 | $ 1.25 | |
Debt unamortized debt discount | $ 286,042 | $ 245,179 | $ 286,042 | ||
Convertible notes payable outstanding | 1,597,500 | 420,000 | 1,597,500 | ||
Convertible Notes Payable One [Member] | |||||
Debt beneficial conversion feature | 104,204 | ||||
Debt amortized debt discount | 356,204 | ||||
Convertible Notes Payable [Member] | |||||
Debt amortized debt discount | 63,342 | 0 | |||
Unsecured Convertible Notes with Related Parties [Member] | |||||
Convertible note principle amount | $ 100,000 | $ 50,000 | $ 250,000 | $ 100,000 | |
Debt interest percentage | 6.00% | 6.00% | 6.00% | 6.00% | |
Increase in interest rate | 12.00% | 12.00% | 12.00% | ||
Maturity date | Nov. 6, 2023 | Nov. 6, 2023 | Nov. 6, 2023 | ||
Conversion exercise price | $ 1.25 | $ 1.25 | $ 1.25 | $ 1.25 | |
Debt amortized debt discount | $ 28,344 | $ 0 | |||
Debt unamortized debt discount | $ 117,105 | $ 154,451 | 117,105 | ||
Convertible notes payable outstanding | 400,000 | 250,000 | 400,000 | ||
Beneficial conversion feature and debt discount | $ 150,000 | ||||
Additional notes related fee | $ 9,000 |
Convertible Note Payable (PIK_4
Convertible Note Payable (PIK Notes) - Schedule of Maturity Date of Notes (Details) | Sep. 30, 2020USD ($) |
Convertible Notes Payable [Member] | |
2021 | |
2022 | |
2023 | |
2024 | 1,597,500 |
2025 | |
Total | 1,597,500 |
Convertible Notes Payable - Related Party [Member] | |
2021 | |
2022 | |
2023 | |
2024 | 400,000 |
2025 | |
Total | $ 400,000 |
Stockholders' Deficit (Details
Stockholders' Deficit (Details Narrative) - USD ($) | Jul. 18, 2020 | Feb. 21, 2020 | Feb. 21, 2020 | Jan. 02, 2020 | Jun. 17, 2019 | Feb. 25, 2019 | Jan. 02, 2019 | Jan. 02, 2017 | Sep. 30, 2020 | Sep. 30, 2019 | Jun. 30, 2020 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2016 |
Stock options outstanding | 5,597,861 | 5,597,861 | 3,835,366 | 3,846,299 | ||||||||||||
Stock options outstanding weighted average exercise price | $ 1.47 | $ 1.47 | $ 1.34 | $ 1.36 | ||||||||||||
Stock options vest and grant date fair value | $ 1.39 | $ 1.46 | ||||||||||||||
Stock options intrinsic value | $ 1,407,792 | $ 1,407,792 | $ 635,536 | |||||||||||||
Number of stock options granted | 1,762,495 | 126,567 | ||||||||||||||
Stock option weighted average exercise price per share | $ 1.75 | $ 1.15 | ||||||||||||||
Stock options granted, term | 6 years 7 days | 7 years 2 months 12 days | ||||||||||||||
Number of stock options vested | 760,488 | 584,895 | ||||||||||||||
Debt amortized debt discount | $ 104,169 | |||||||||||||||
Warrants [Member] | ||||||||||||||||
Warrants to purchase shares | 100,000 | 100,000 | 98,800 | 81,600 | 98,800 | |||||||||||
Warrant exercise price | $ 1.25 | $ 1.25 | $ 1.25 | $ 1.25 | $ 1.25 | |||||||||||
Class of warrant or right, expiration period | 5 years | 5 years | ||||||||||||||
Class of warrant or right, outstanding | 4,007,058 | 4,007,058 | 3,826,658 | |||||||||||||
Class of warrant or right, outstanding, weighted average exercise price | $ 1.06 | $ 1.06 | $ 1.05 | |||||||||||||
Class of warrant or right, outstanding, intrinsic value | $ 643,130 | $ 643,130 | $ 1,375,990 | |||||||||||||
Class of warrant or right, expiration period, description | The expiration date was extended by two years from January 2, 2020 to January 2, 2022. | |||||||||||||||
Warrant [Member] | ||||||||||||||||
Debt amortized debt discount | $ 5,840 | 0 | ||||||||||||||
Series B Preferred Stock [Member] | Placement Agent Warrants [Member] | ||||||||||||||||
Warrants to purchase shares | 127,346 | 127,346 | ||||||||||||||
Warrant exercise price | $ 1.25 | $ 1.25 | ||||||||||||||
Series B Preferred Stock [Member] | Private Placement [Member] | ||||||||||||||||
Warrants to purchase shares | 423,291 | 423,291 | ||||||||||||||
Warrant exercise price | $ 1.25 | |||||||||||||||
Series B Preferred Stock [Member] | Private Placement [Member] | Protagenic Warrants [Member] | ||||||||||||||||
Warrants to purchase shares | 3,403,367 | 3,403,367 | ||||||||||||||
Warrant exercise price | $ 1.05 | $ 1.05 | ||||||||||||||
Class of warrant or right, expiration period | 5 years | |||||||||||||||
Options To Related Party [Member] | ||||||||||||||||
Share-based payment award, expiration period | 10 years | |||||||||||||||
Stock options outstanding | 124,998 | |||||||||||||||
Stock options outstanding weighted average exercise price | $ 1.75 | |||||||||||||||
Dr. Buell [Member] | ||||||||||||||||
Share-based payment award, expiration period | 48 months | |||||||||||||||
Stock options outstanding | 100,000 | |||||||||||||||
Stock options outstanding weighted average exercise price | $ 1.75 | |||||||||||||||
Additional Issuance of Warrants for Debt [Member] | Series B Preferred Stock [Member] | Private Placement [Member] | Protagenic Warrants [Member] | ||||||||||||||||
Debt instrument, face amount | $ 665,000 | $ 665,000 | ||||||||||||||
Additional Issuance of Warrants for Accrued Interest [Member] | Series B Preferred Stock [Member] | Private Placement [Member] | Protagenic Warrants [Member] | ||||||||||||||||
Accrued interest | $ 35,000 | $ 35,000 | ||||||||||||||
Additional Issuance of Warrants [Member] | Series B Preferred Stock [Member] | Private Placement [Member] | Protagenic Warrants [Member] | ||||||||||||||||
Warrants to purchase shares | 295,945 | 295,945 | ||||||||||||||
Warrant exercise price | $ 1.25 | $ 1.25 | ||||||||||||||
Employees [Member] | ||||||||||||||||
Compensation expense | $ 351,696 | $ 858,884 | ||||||||||||||
Unamortized stock option expense | 563,267 | 563,267 | ||||||||||||||
Non-Employees [Member] | ||||||||||||||||
Compensation expense | 106,871 | 264,267 | ||||||||||||||
Unamortized stock option expense | 138,724 | 138,724 | ||||||||||||||
Stock Options [Member] | ||||||||||||||||
Share-based payment award, expiration period | 10 years | |||||||||||||||
Stock options outstanding | 105,000 | |||||||||||||||
Stock options outstanding weighted average exercise price | $ 1.75 | |||||||||||||||
Compensation expense | 458,567 | $ 139,066 | 1,123,151 | $ 850,767 | ||||||||||||
Unamortized stock option expense | $ 701,991 | $ 701,991 | ||||||||||||||
Number of stock options granted | 1,762,495 | 126,567 | ||||||||||||||
Stock option weighted average exercise price per share | $ 1 | $ 1.75 | ||||||||||||||
Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition | 2 years 1 month 6 days | |||||||||||||||
Stock Options [Member] | ||||||||||||||||
Number of stock options granted | 25,000 | 101,567 | ||||||||||||||
Stock option weighted average exercise price per share | $ 1.75 | $ 1 | ||||||||||||||
Stock options fair value | $ 36,374 | $ 199,807 | ||||||||||||||
Stock options granted, term | 10 years | 10 years | ||||||||||||||
Number of stock options vested | 59,900 | |||||||||||||||
Number of options shares issued for settlement | 59,900 | |||||||||||||||
Settlement amount | $ 29,850 | |||||||||||||||
Loss in settlement | $ 99,541 | |||||||||||||||
Stock Options [Member] | Settlement of Accrued Compensation [Member] | ||||||||||||||||
Compensation expense | $ 93,950 | |||||||||||||||
Number of stock options granted | 187,497 | |||||||||||||||
Stock options fair value | $ 1,901,724 | |||||||||||||||
Stock Options [Member] | Vest bi-Weekly Over Two Months [Member] | ||||||||||||||||
Number of stock options vested | 41,667 | |||||||||||||||
Stock Options [Member] | Options Vested Immediately [Member] | ||||||||||||||||
Number of stock options vested | 187,497 | |||||||||||||||
Stock Options [Member] | Options Vested Immediately [Member] | Options To Related Party [Member] | ||||||||||||||||
Stock options vest and grant date fair value | 142,607 | |||||||||||||||
Stock Options [Member] | Options Vested Over 12 Months [Member] | ||||||||||||||||
Number of stock options vested | 510,000 | |||||||||||||||
Stock Options [Member] | Options Vested Over 24 Months [Member] | ||||||||||||||||
Number of stock options vested | 5,000 | |||||||||||||||
Stock Options [Member] | Options Vested Over 36 Months [Member] | ||||||||||||||||
Number of stock options vested | 420,000 | |||||||||||||||
Stock Options [Member] | Options Vested Over 48 Months [Member] | ||||||||||||||||
Number of stock options vested | 265,000 | |||||||||||||||
Stock Options [Member] | Options Vested [Member] | ||||||||||||||||
Stock options vest and grant date fair value | 119,972 | |||||||||||||||
Stock Options [Member] | Options Vested [Member] | Dr. Buell [Member] | ||||||||||||||||
Stock options vest and grant date fair value | $ 165,426 | |||||||||||||||
Stock Options [Member] | Sixteen Individuals [Member] | ||||||||||||||||
Number of stock options granted | 1,387,497 | |||||||||||||||
Stock option weighted average exercise price per share | $ 1.75 | |||||||||||||||
Stock Options [Member] | Twelve Related Parties [Member] | ||||||||||||||||
Number of stock options granted | 1,362,497 | |||||||||||||||
Stock option weighted average exercise price per share | $ 1.75 | |||||||||||||||
Recognition Upcoming Service [Member] | Dr. Buell [Member] | ||||||||||||||||
Share-based payment award, expiration period | 12 months | |||||||||||||||
Stock options outstanding | 45,000 | |||||||||||||||
Black-Scholes Model [Member] | Warrant [Member] | ||||||||||||||||
Warrants to purchase shares value | $ 86,968 | |||||||||||||||
June 30, 2020 [Member] | Warrant [Member] | ||||||||||||||||
Debt amortized debt discount | $ 6,643 | $ 0 | ||||||||||||||
Black-Scholes Model Two [Member] | Warrant [Member] | ||||||||||||||||
Warrants to purchase shares value | $ 105,194 | |||||||||||||||
The 2016 Plan [Member] | ||||||||||||||||
Number of additional shares grants for issuance | 567,378 | 564,378 | 564,378 | |||||||||||||
Number of shares available for grant | 1,693,134 | 1,693,134 | 1,693,134 | 4,868,623 | 4,868,623 | 4,304,245 | ||||||||||
Share-based payment award, expiration period | 10 years |
Stockholders' Deficit - Schedul
Stockholders' Deficit - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2020 | Dec. 31, 2019 | |
Exercise price | $ 1.75 | |
Expected dividend yield | 0.00% | 0.00% |
Expected life in years | 10 years | 10 years |
Minimum [Member] | ||
Exercise price | $ 1 | |
Risk free interest rate | 0.64% | 2.09% |
Expected volatility | 140.00% | 137.00% |
Maximum [Member] | ||
Exercise price | $ 1.75 | |
Risk free interest rate | 1.61% | 2.70% |
Expected volatility | 146.00% | 140.00% |
Stockholders' Deficit - Sched_2
Stockholders' Deficit - Schedule of Share-based Compensation, Stock Options, Activity (Details) - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2020 | Dec. 31, 2019 | |
Equity [Abstract] | ||
Stock Options Outstanding, Beginning | 3,835,366 | 3,846,299 |
Stock Options, Granted | 1,762,495 | 126,567 |
Stock Options, Expired | (137,500) | |
Stock Options Outstanding, Ending | 5,597,861 | 3,835,366 |
Weighted Average Exercisable Price, Stock Options Outstanding, Beginning | $ 1.34 | $ 1.36 |
Weighted Average Exercisable Price, Stock Options Outstanding, Granted | 1.75 | 1.15 |
Weighted Average Exercisable Price, Stock Options Outstanding, Expired | 1.75 | |
Weighted Average Exercisable Price, Stock Options Outstanding, Ending | $ 1.47 | $ 1.34 |
Weighted Average Remaining Life, Stock Options Outstanding, Beginning | 6 years 7 days | 7 years 2 months 12 days |
Weighted Average Remaining Life, Stock Options Outstanding, Granted | 9 years 5 months 20 days | 9 years 2 months 12 days |
Weighted Average Remaining Life, Stock Options Outstanding, Ending | 6 years 8 months 26 days | 6 years 7 days |
Stockholders' Deficit - Sched_3
Stockholders' Deficit - Schedule of Share-based Compensation Nonvested Shares (Details) - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2020 | Dec. 31, 2019 | |
Equity [Abstract] | ||
Nonvested Options, Beginning Balance | 204,382 | 800,210 |
Nonvested Options, Granted | 1,762,495 | 126,567 |
Nonvested Options, Vested | (760,488) | (584,895) |
Nonvested Options, Forfeited | (137,500) | |
Nonvested Options, Ending Balance | 1,206,389 | 204,382 |
Weighted Average Exercise Price, Beginning Balance | $ 1.74 | $ 1.63 |
Weighted Average Exercise Price, Granted | 1.75 | 1.15 |
Weighted Average Exercise Price, Vested | 1.39 | 1.46 |
Weighted Average Exercise Price, Forfeited | 1.75 | |
Weighted Average Exercise Price, Ending Balance | $ 1.75 | $ 1.74 |
Stockholders' Deficit - Summary
Stockholders' Deficit - Summary of Warrant Issuances (Details) - $ / shares | 9 Months Ended | 12 Months Ended |
Sep. 30, 2020 | Dec. 31, 2019 | |
Equity [Abstract] | ||
Number of Warrants Outstanding, Beginning | 3,826,658 | 3,826,658 |
Number of Warrants Outstanding, Granted | 180,400 | |
Number of Warrants Outstanding, Ending | 4,007,058 | 3,826,658 |
Number of Warrants Outstanding, Weighted Average Exercise Price, Beginning | $ 1.05 | $ 1.05 |
Number of Warrants Outstanding, Weighted Average Exercise Price, Granted | 1.25 | |
Number of Warrants Outstanding, Weighted Average Exercise Price, Ending | $ 1.06 | $ 1.05 |
Number of Warrants Outstanding, Weighted Average Remaining Life | 2 years 8 months 9 days | 3 years 8 months 9 days |
Number of Warrants Outstanding, Weighted Average Remaining Life Granted | 5 years | |
Number of Warrants Outstanding, Weighted Average Remaining Life | 2 years 1 month 13 days | 2 years 8 months 9 days |
Collaborative Agreements (Detai
Collaborative Agreements (Details Narrative) - USD ($) | Feb. 25, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019 | Dec. 31, 2015 |
Number of stock options vested | 760,488 | 584,895 | |||||
Research and development expense | $ 539,770 | $ 31,153 | $ 657,737 | $ 291,828 | |||
Research Agreements [Member] | |||||||
Research and development expense | $ 0 | $ 63,787 | |||||
Stock Options [Member] | |||||||
Number of stock options vested | 59,900 | ||||||
University of Toronto [Member] | |||||||
Share-based compensation stock options, grants | 25,000 | ||||||
Share-based compensation weighted average exercise price | $ 1 | ||||||
Share-based payment award, expiration period | 10 years | ||||||
Options expiration date, description | Exercisable over a ten year period which ends on April 1, 2022. | ||||||
Dr. David Lovejoy [Member] | Stock Options [Member] | |||||||
Share-based compensation stock options, grants | 553,299 | ||||||
Share-based compensation weighted average exercise price | $ 1 | $ 1 | |||||
Options expiration date, description | These have an exercise price of $1.00, $1.25 or 1.75 and are exercisable over ten or thirteen year periods which end either on March 30, 2021, December 1, 2022, April 15, 2026, March 1, 2027 or on October 16, 2027. | ||||||
Number of stock options vested | 517,987 | ||||||
Dr. David Lovejoy [Member] | Stock Options [Member] | Minimum [Member] | |||||||
Share-based compensation weighted average exercise price | 1.25 | $ 1.25 | |||||
Dr. David Lovejoy [Member] | Stock Options [Member] | Maximum [Member] | |||||||
Share-based compensation weighted average exercise price | $ 1.75 | $ 1.75 |
Licensing Agreements (Details N
Licensing Agreements (Details Narrative) - USD ($) | 9 Months Ended | |
Sep. 30, 2020 | Sep. 30, 2019 | |
Royalty payment on behalf of sub-licensee, percentage | 2.50% | |
Sales revenue | ||
Interest on amounts owed under license agreement, rate | 3.00% | |
Licensing Agreements [Member] | ||
Royalty payment, percentage | 2.50% | |
Up-front sub-license fees, percentage | 10.00% |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - $ / shares | Jul. 18, 2020 | Feb. 13, 2020 | Sep. 30, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Number of stock options granted | 1,762,495 | 126,567 | |||
Stock options outstanding weighted average exercise price | $ 1.47 | $ 1.34 | $ 1.36 | ||
Option term | 6 years 7 days | 7 years 2 months 12 days | |||
Stock options outstanding | 5,597,861 | 3,835,366 | 3,846,299 | ||
Stock options vest and grant date fair value | $ 1.39 | $ 1.46 | |||
Dr. Buell [Member] | |||||
Stock options outstanding weighted average exercise price | $ 1.75 | ||||
Option term | 48 months | ||||
Stock options outstanding | 100,000 | ||||
Dr. Buell [Member] | Recognition Upcoming Service [Member] | |||||
Option term | 12 months | ||||
Stock options outstanding | 45,000 | ||||
Dr. Buell [Member] | Recognition Upcoming Service [Member] | Options Vested [Member] | |||||
Stock options vest and grant date fair value | $ 165,426 | ||||
Related Party [Member] | |||||
Number of stock options granted | 50,000 | ||||
Stock options outstanding weighted average exercise price | $ 1.75 | ||||
Option term | 48 months |